grants from National Natural Science Foundation of China(No.82373222,No.82202970);Leading Talent Program by Shanghai Municipal Health Commission(2022LJ008,China);Shanghai Shenkang Hospital Development Center(SHDC12021104,China);Science and Technology Commission of Shanghai Municipality(22Y21900200&22YF1404300,China).
Tumor relapse and metastasis are the major causes of mortality associated with urothelial cancer.In the tumor microenvironment,negative regulatory molecules and various immune cell subtypes suppress antitumor immunity...
supported by the National Basic Research Program of China(Nos.2021YFA1201404,and 2019YFA0210103);the National Natural Science Foundation of China(Nos.32271413,and 82272492);Natural Science Foundation of Jiangsu Province(No.BK20232023);Science program of Jiangsu Province Administration for Market Regulation(No.KJ2024010).
Bone tissue engineering provides a promising strategy for the treatment of bone defects.Nonetheless,the clinical utilization of biomaterial-based scaffolds is constrained by their inadequate mechanical strength and ab...
BACKGROUND The prognosis of hepatocellular carcinoma(HCC)combined with portal and hepatic vein cancerous thrombosis is poor,for unresectable patients the combination of targeted therapy and immune therapy was the firs...
supported by the National Natural Science Foundation of China(52103181,81873196);the Sino-German Center for Research Promotion(GZ1505);the Fundamental Research Funds for the Central Universities(22120220075);the China Scholarship Council(201908320330)。
Traditional treatments for advanced hepatocellular carcinoma(HCC),such as surgical resection,transplantation,radiofrequency ablation,and chemotherapy are unsatisfactory,and therefore the exploration of powerful therap...
Sorafenib remains the standard systemic treatment for advanced human hepatocellular carcinoma(HCC).However,the low response rate,high recurrence,and high progression limit the therapeutic efficacy.Therefore,a combinat...
supported by the National Key Research and Development Program of China (2018YFA0900700);the National Natural Science Foundation of China (31901021 and 31921006);the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB27020206);the International Partnership Program of Chinese Academy of Sciences (153D31KYSB20170121);the Strategic Biological Resources Service Network Plan of the Chinese Academy of Sciences (KFJ-BRP-009)。
Icaritin is a prenylflavonoid present in the Chinese herbal medicinal plant Epimedium spp. and is under investigation in a phase Ⅲ clinical trial for advanced hepatocellular carcinoma. Here, we report the biosynthesi...
This work was financially supported by the National Natural Science Foundation of China(Grant No.81770580);open funding from the Sichuan Provincial Key Laboratory of Radiation Oncology(Grant No.2020FSZLX-02).
Background and Aims:Lipid accumulation is the major characteristic of non-alcoholic fatty liver disease,the prevalence of which continues to rise.We aimed to investigate the effects and mechanisms of icaritin on lipid...
Supported by the National Natural Science Foundation of China(No.21672203).
Natural products icaritin and β-anhydroicaritin with P-glycoprotein(P-gp) inhibitory activities were ciently synthesized in nine steps from commercially available phloroglucinol. A modified Algar-Flynn-Oyamada cycliz...
supported by the National Natural Science Foundation of China (NSFC) [No. 81430095]
Objective: To identify the in vivo metabolites of icaritin and speculate its metabolic profiling in rats.Methods: The plasma, bile, urine, and feces of rats were collected after orally administration of icaritin at a ...
financially supported by the Natural Foundation of Shandong Province (ZR2015QL002)
Objective: To investigate the protective effects of icaritin (ICT), one of the active ingredients in Epimedii Folium, on mouse model of cerebral ischemia-reperfusion (I/R) in vivo. Methods: ICR mice were subject...